Chlorpromazine metabolism in humans. Part I

1973 ◽  
Vol 61 (3) ◽  
pp. 435-452 ◽  
Author(s):  
T. L. Chan ◽  
Samuel Gershon
1971 ◽  
Vol 119 (553) ◽  
pp. 589-596 ◽  
Author(s):  
S. Sved ◽  
A. Perales ◽  
D. Palaic

At present the phenothiazine drugs constitute the medication of choice in the treatment of schizophrenia. While in most schizophrenics treatment with phenothiazines does ameliorate the symptoms of the disease there are a certain number of patients who remain resistant to therapy. In such patients the side effects caused by phenothiazines may also be less pronounced or completely absent.


1972 ◽  
Vol 61 (4) ◽  
pp. 581-585 ◽  
Author(s):  
Pushkar N. Kaul ◽  
Michael W. Conway ◽  
Maharaj K. Ticku ◽  
Mervin L. Clark

1970 ◽  
Vol 59 (12) ◽  
pp. 1745-1749 ◽  
Author(s):  
Pushkar N. Kaul ◽  
Michael W. Conway ◽  
Mervin L. Clark ◽  
James Huffine

1972 ◽  
Vol 120 (556) ◽  
pp. 356-356
Author(s):  
Gerald Samuel ◽  
Graham Mould

The paper by Sved et al. (1) serves as a further reminder of the need for the monitoring of drugs used in psychiatry. We would however urge great caution in accepting the conclusions which the authors draw regarding resistance to chlorpromazine therapy. We fear a turn sequitur.


1965 ◽  
Vol 3 (1) ◽  
pp. 27-35 ◽  
Author(s):  
Albert A. Kurland ◽  
Chian L. Huang ◽  
Kenneth J. Hallam ◽  
Thomas E. Hanlon

Sign in / Sign up

Export Citation Format

Share Document